In the last trading session, 1.42 million shares of the Prime Medicine Inc (NASDAQ:PRME) were traded, and its beta was 1.88. Most recently the company’s share price was $2.28, and it changed around -$0.14 or -5.79% from the last close, which brings the market valuation of the company to $299.05M. PRME currently trades at a discount to its 52-week high of $9.77, offering almost -328.51% off that amount. The share price’s 52-week low was $2.37, which indicates that the current value has fallen by an impressive -3.95% since then. We note from Prime Medicine Inc’s average daily trading volume that its 10-day average is 0.95 million shares, with the 3-month average coming to 1.13 million.
Prime Medicine Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended PRME as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Prime Medicine Inc is expected to report earnings per share of -0.31 for the current quarter.
Prime Medicine Inc (NASDAQ:PRME) trade information
Instantly PRME has showed a red trend with a performance of -5.79% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.75 on recent trading dayincreased the stock’s daily price by 17.09%. The company’s shares are currently down -21.92% year-to-date, but still down -11.97% over the last five days. On the other hand, Prime Medicine Inc (NASDAQ:PRME) is -22.45% down in the 30-day period. We can see from the shorts that 17.3 million shares have been sold at a short interest cover period of 20.76 day(s).
The consensus price target as assigned by Wall Street analysts is $17, which translates to bulls needing to increase their stock price by 86.59% from its current value. Analyst projections state that PRME is forecast to be at a low of $12 and a high of $23.
Prime Medicine Inc (PRME) estimates and forecasts
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 5.81M in revenue for the current quarter. 5 analysts expect Prime Medicine Inc to make 4.55M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 669.88%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -193.88%. Prime Medicine Inc earnings are expected to increase by 26.60% in 2025, but the outlook is positive 20.17% per year for the next five years.
PRME Dividends
Prime Medicine Inc’s next quarterly earnings report is expected to be released in March.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 23.91% of Prime Medicine Inc shares, and 61.51% of them are in the hands of institutional investors. The stock currently has a share float of 80.83%.
ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF were the top two Mutual Funds as of Dec 31, 2024. The former held 2.41 shares worth $5.5 million, making up 1.84% of all outstanding shares. On the other hand, ARK ETF Tr-ARK Innovation ETF held roughly 2.23 shares worth around $5.08 million, which represents about 1.70% of the total shares outstanding.
